Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 28 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing final approvals from the USFDA for Ivermectin Tablets and Dapsone Tablets. The Ivermectin Tablets are indicated for treating parasitic worm infections, while Dapsone Tablets are used for leprosy and dermatitis herpetiformis. Both products will be manufactured in Ahmedabad and distributed by Viona Pharmaceuticals Inc.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases